Çetin Ç.B.Özer Türk D.Şenol Ş.Dinç Horasan G.Tünger Ö.2024-07-222024-07-22201613000144http://akademikarsiv.cbu.edu.tr:4000/handle/123456789/16068Background/aim: Colistin is used as a salvage therapy for multidrug-resistant and extremely drug-resistant gram-negative bacterial infections. Our aim was to evaluate colistin efficiency and toxicity in the treatment of these resistant gram-negative bacterial infections. Materials and methods: This is a retrospective study carried out in a tertiary care hospital during 2011–2013. Study data were collected from the medical records and consultations of the infectious diseases clinic. Results: The study group included 158 patients with nosocomial infections and 136 (86.1%) of them were hospitalized in the ICU. Respiratory tract infections were the most commonly observed ones (n = 103, 65.2%). The most frequently isolated microorganism was Acinetobacter baumannii (72.2%). A total of 98 (62.0%) patients had clinical cure. There was no statistically significant difference between monotherapy (n = 3/6, 50.0%) and combination therapies (n = 95/152, 62.5%) according to clinical response. Underlying ultimately fatal disease, previous renal disease, and total parenteral nutrition were independent risk factors for poor clinical response. Nephrotoxicity developed in 80 (50.6%) patients and clinical cure was statistically unrelated with nephrotoxicity. Conclusion: Colistin may be used as an effective agent for multidrug-resistant and extremely drug-resistant gram-negative bacterial infections with close monitoring of renal functions, especially for older and critically ill patients. © TÜBİTAK.EnglishAll Open Access; Hybrid Gold Open AccessAcinetobacter baumanniiAnti-Bacterial AgentsColistinDrug Resistance, Multiple, BacterialGram-Negative Bacterial InfectionsHumansRetrospective StudiesTreatment Outcomecolistinantiinfective agentcolistinAcinetobacter baumanniiadultagedArticleartificial ventilationchronic kidney diseasedrug dose reductiondrug efficacydrug withdrawalEscherichia colifemaleGram negative infectionhumanKlebsiella pneumoniaemajor clinical studymalemonotherapymultidrug resistancenephrotoxicityparenteral nutritionPseudomonas aeruginosarespiratory tract infectionretrospective studyrisk factortreatment outcomeGram negative infectionColistin efficacy in the treatment of multidrug-resistant and extremely drug-resistant gram-negative bacterial infectionsArticle10.3906/sag-1506-125